'It is admitted that the AZ vaccine can, in very rare cases, cause TTS.'
Pharma giant AstraZeneca's Covid-19 vaccine is being withdrawn worldwide after the company acknowledged for the first time in court documents that it can cause a rare and dangerous side effect, according to a report in the British newspaper The Telegraph.
United Kingdom-headquartered pharmaceutical giant AstraZeneca (AZ) has admitted that in 'very rare cases' its Covid vaccine can cause a blood clot related side effect but the causal link is unknown, according to court papers being quoted in the UK media.
AstraZeneca Pharma India, the Indian subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, has decided to delist its scrip from the Bombay Stock Exchange, National Stock Exchange and Bangalore Stock Exchange.
Under the terms of the deal Ranbaxy will drop litigation it initiated in November 2005 and will sell Nexium from May 2014 - the expiry date of the first of a series of patents. Under US law Ranbaxy would be the exclusive generic distributor for the first six months.
Britain's AstraZeneca on Monday rejected a sweetened and "final" offer from Pfizer , casting serious doubt on the U.S. drugmaker's plan for a merger to create the world's biggest pharmaceuticals group.
Despite these rare occurrences, the pharmaceutical company maintains that extensive clinical trial data and real-world evidence consistently support the vaccine's safety and efficacy.
AstraZeneca Pharma India 35 per cent dividend for fiancial year 2002.
Drugmaker Aurobindo Pharma on Monday said it has entered into licensing and supply agreements with London-based pharmaceutical giant AstraZeneca to supply several solid dosage and sterile products for emerging markets.
The researchers analysed 2580,021 test results from nose and throat swabs taken from 384,543 participants aged 18 years or older between December 1, 2020 and May 16, 2021.
We have applied for marketing authorisation to the EMA through AstraZeneca. We will not sell the vaccine in the EU, said a company source.
Researchers at Public Health Scotland and the University of Edinburgh, UK, found that the Pfizer-BioNTech vaccine offered better protection against the Delta variant compared to the Oxford-AstraZeneca preventive, known as Covishield in India.
AstraZeneca and the University of Oxford, as the trial sponsor, said that they cannot disclose further medical information but confirmed that independent investigations concluded that the trials were safe to restart.
The phase 3 trial is being implemented as part of Operation Warp Speed, a multi-agency collaboration led by the US Health and Human Services, which aims at accelerating the development and manufacturing of medical countermeasures for COVID-19 and delivering 300 million doses of an effective vaccine by January 2021.
But no extra risk after second dose, shows study led and funded by drug maker, reports Sohini Das.
AstraZeneca has stressed that patient safety is its "highest priority" and pointed out that regulators around the world "consistently state that the benefits of vaccination outweigh the risks of extremely rare potential side effects".
The study also noted that the booster dosage of the company's COVID-19 vaccine Vaxzevria also increased the immune response to Beta, Delta, Alpha and Gamma SARS-CoV-2 variants.
Backing the 12-16 weeks gap between the two doses of Covishield in the country, the chief investigator of the AstraZeneca vaccine clinical trials on Friday said that the level of protection provided by one dose of the preventive significantly increases in the second and third months after the jab.
Global pharma firm AstraZeneca on Tuesday said it had filed a lawsuit in the United States District Court of New Jersey
The UK's National Health Service was already lining up thousands of medics and volunteers to be ready to deliver jabs up and down the country.
The British-Swedish pharmaceutical major and the UK's medicines regulator said that the vaccines produced by Oxford University in collaboration with AstraZeneca to protect against COVID-19 are safe.
Close on the heels of introducing drugs for treatment of cancer and cardiovascular diseases, Anglo-Swedish pharmaceutical major AstraZeneca on Tuesday said it would launch one more medicine this year and two next year in India.
Under the agreement, MedImmune has granted Sun Pharma a licence to certain patents, permitting Sun Pharma to continue marketing its generic version of Ethyol in the US.
The institute expects to complete both, phase-2 and 3 trials in India by the end of this year.
The Oxford vaccine, which also has a tie-up with the Serum Institute of India, was first administered to Brian Pinker, an 82-year-old Oxford-born dialysis patient. Pinker is among the first to be vaccinated by the Oxford University Hospital's (OUH) chief nurse, hailed as a major milestone in the phased vaccination programme being undertaken by the National Health Service (NHS).
The Medicines and Healthcare Products Regulatory Agency said in its latest Yellow Card monitoring of the coronavirus vaccine programme this week that of the 18.1 million people who had the Oxford vaccine in the UK, 30 people developed blood clots and seven had died as of March 24.
'This will not be the last time a virus threatens our lives and our livelihoods'
Combine a robust base health plan with a super top-up, critical illness cover and a dedicated medical corpus to protect household finances from soaring treatment costs.
AstraZeneca on Wednesday announced that it had filed separate patent infringement actions in the United States District Court, Delaware, against seven generic drug manufacturers, which have submitted abbreviated new drug applications (ANDAs) with the US Food and Drug Administration (FDA) seeking marketing authorisation for Crestor.
Karnataka Chief Minister Siddaramaiah alleged that the rushed approval and distribution of the COVID-19 vaccine may be a contributing factor to cardiac arrest deaths, citing several international studies that recently suggested a possible link between the vaccines and a rise in heart attacks.
"I've just received my first Oxford/AstraZeneca vaccine dose. Thank you to all of the incredible scientists, NHS staff and volunteers who helped make this happen," he tweeted. "Getting the jab is the best thing we can do to get back to the lives we miss so much. Let's get the jab done," he added in his tweet.
'India is clearly moving toward more targeted treatment pathways in high-burden cancers.'
Following up first doses of the AstraZeneca or Pfizer vaccines with second doses of the Moderna or Novavax jabs generates robust immune response against COVID-19, according to a study published in The Lancet journal.
AstraZeneca Plc and the University of Oxford are facing questions about their Covid-19 vaccine and whether regulators would quickly authorise its emergency use after the pharma company acknowledged an error in the vaccine dosage received by some participants and other irregularities and omissions, according to the New York Times.
SII would be scaling up its AstraZeneca-Oxford vaccine manufacturing capacity to 200 million doses a month from 100 million a month now, reports Sohini Das.
After Chennai, it is Coimbatore, Madurai, and Tiruchirappalli, that are emerging as manufacturing hubs. Coimbatore is India's top Tier-II city in terms of the number of GCCs, according to a report by Cushman & Wakefield.
